These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 28025078)

  • 1. Analysis of KRAS, NRAS, PIK3CA, and BRAF mutational profile in poorly differentiated clusters of KRAS-mutated colon cancer.
    Reggiani Bonetti L; Barresi V; Bettelli S; Caprera C; Manfredini S; Maiorana A
    Hum Pathol; 2017 Apr; 62():91-98. PubMed ID: 28025078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS, NRAS, BRAF mutations and high counts of poorly differentiated clusters of neoplastic cells in colorectal cancer: observational analysis of 175 cases.
    Barresi V; Bonetti LR; Bettelli S
    Pathology; 2015 Oct; 47(6):551-6. PubMed ID: 26352110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
    Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
    PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined detection of KRAS, NRAS, BRAF and PIK3CA mutations in the plasma and tumor tissues of colorectal cancer patients].
    Liu XN; Tian Z; Wei XF; Wang Q; Zhang JX; Jin MS; Duan XM
    Zhonghua Bing Li Xue Za Zhi; 2019 May; 48(5):373-377. PubMed ID: 31104677
    [No Abstract]   [Full Text] [Related]  

  • 6. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
    Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
    Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
    Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
    BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
    Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
    J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial.
    Santos C; Azuara D; Viéitez JM; Páez D; Falcó E; Élez E; López-López C; Valladares M; Robles-Díaz L; García-Alfonso P; Bugés C; Durán G; Salud A; Navarro V; Capellá G; Aranda E; Salazar R
    Ann Oncol; 2019 May; 30(5):796-803. PubMed ID: 30840064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
    Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
    Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
    Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
    Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
    Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
    Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
    Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS, NRAS, BRAF, and PIK3CA mutation rates, clinicopathological association, and their prognostic value in Iranian colorectal cancer patients.
    Mirzapoor Abbasabadi Z; Hamedi Asl D; Rahmani B; Shahbadori R; Karami S; Peymani A; Taghizadeh S; Samiee Rad F
    J Clin Lab Anal; 2023 Mar; 37(5):e24868. PubMed ID: 36930789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients.
    Hsu HC; Thiam TK; Lu YJ; Yeh CY; Tsai WS; You JF; Hung HY; Tsai CN; Hsu A; Chen HC; Chen SJ; Yang TS
    Oncotarget; 2016 Apr; 7(16):22257-70. PubMed ID: 26989027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients.
    Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W
    J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.
    Zhang J; Zheng J; Yang Y; Lu J; Gao J; Lu T; Sun J; Jiang H; Zhu Y; Zheng Y; Liang Z; Liu T
    Sci Rep; 2015 Dec; 5():18678. PubMed ID: 26691448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.